The latest trading day saw Pfizer (PFE) settling at $25.60, representing a -0.43% change from its previous close.

Over the past six decades, hundreds of millions of people have taken Xanax or one of its relatives in the benzodiazepine family for a range of ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Sponsored by the Indian Council of Social Science Research (ICSSR), the seminar served as a platform for experts, researchers, and students to discuss the role of artificial intelligence (AI) in ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

A 400-home neighbourhood at Hazelhurst Farm in Worsley, a site allocated in Greater Manchester’s Places for Everyone development plan, will go to committee for a decision next week.

Núñez Feijóo, the leader of the Spanish People's Party (Partido Popular/EPP), the main opposition force in Parliament, met with Sánchez (PSOE/S&D) for talks on how the government intends to reach its ...

This article has been corrected to reflect that the senators asked UpScriptHealth to respond. In August 2024, Pfizer Inc ...

Pfizer has terminated a Phase I trial of its investigational STING therapy in advanced solid tumors, according to an update ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

SoundHound AI, Inc. (Nasdaq: SOUN), a global leader in voice artificial intelligence, today announced its participation in the 2025 NVIDIA GPU Technology Conference (GTC), from March 17-21 in San Jose ...